Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer

Hu, ZY; Zheng, CJ; Yang, JB; Ding, SY; Tian, C; Xie, N; Xue, L; Wu, MY; Fu, SJ; Rao, ZZ; Price, MA; McCarthy, JB; Ouyang, QC; Lin, JZ; Deng, XY

Ouyang, QC (通讯作者)，Cent South Univ, Xiangya Med Sch, Hunan Canc Hosp, Changsha, Peoples R China.;Ouyang, QC (通讯作者)，Cent South Univ, Affiliated Canc Hosp, Changsha, Peoples R China.;Ouyang, QC (通讯作者)，Hunan Canc Hosp, Dept Breast Canc Med Oncol, Changsha, Peoples R China.;Ouyang, QC (通讯作者)，Cent South Univ, Dept Breast Canc Med Oncol, Affiliated Canc Hosp, Xiangya Med Sch, Changsha, Peoples R China.;Deng, XY (通讯作者)，Hunan Normal Univ, Sch Med, Key Lab Model Animals & Stem Cell Biol Hunan Prov, Dept P

FRONTIERS IN ONCOLOGY, 2022; 12 ():

Abstract

BackgroundIn triple-negative breast cancer (TNBC), PDL1/PD1-directed immunotherapy is effective in less than 20% of patients. In our preliminary study......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索